Although the bacille Calmette-Guérin (BCG) vaccine is used primarily to protect against tuberculosis, previous research has suggested it might also guard against other infections. At the start of the COVID-19 pandemic, researchers hypothesized that vaccination with BCG, which seems to cause epigenetic changes in immune cells that promote a stronger immune response against pathogens, might be effective against COVID-19.
However, the BCG-Denmark vaccine does not result in a lower risk of symptomatic or severe COVID-19 within 6 months of administration, according to a randomized clinical trial that included 3988 health care workers. There was no evidence of vaccine-related adverse effects, the researchers reported in the New England Journal of Medicine.
Published Online: May 3, 2023. doi:10.1001/jama.2023.7763